The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2006
Filed:
Jan. 25, 2002
Jeffrey Schlom, Potomac, MD (US);
Judith Kantor, Rockville, MD (US);
Donald Kufe, Wellesley, MA (US);
Dennis Panicali, Acton, MA (US);
Linda Gritz, Somerville, MA (US);
Jeffrey Schlom, Potomac, MD (US);
Judith Kantor, Rockville, MD (US);
Donald Kufe, Wellesley, MA (US);
Dennis Panicali, Acton, MA (US);
Linda Gritz, Somerville, MA (US);
Therion Biologics Corporation, Cambridge, MA (US);
Dana-Farber Cancer Institute, Boston, MA (US);
The United States of America as represented by the Department of Health and Human Services, Washington, DC (US);
Abstract
Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.